undamentalytics Newsletter
Sign in

Supernus Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Supernus Pharmaceuticals, Inc. had total assets of $1.45bn, total liabilities of $391m and shareholders' equity of $1.06bn. It held $128m in cash against $0 of debt: net cash of $128m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents24494033363366100192181289203937569128176
Receivables—0051726426710387141149165144142188215
Inventory——171313171626274886927754112113
Total current assets—499197109106151228493473630602734493686644711
Goodwill—————————078118117117117125119
Total assets—54941111371893104249781,1601,5041,6891,7031,2781,3681,4531,398
Accounts payable———3248731069112539
Deferred revenue (current)—01————0—————————
Total current liabilities—192326285781123161161245315688290292338285
Short-term debt———————————0—————
Long-term debt——23342674—3293453623790————
Total debt023233426741329345362379402—000
Total liabilities—44367896101118157525565759873816356332391335
Shareholders' equity−449583341881922674535957458168869221,0361,0621,062
Net debt (negative = net cash)−24−26−171−10−26−62−9913716473176309−75−69−128−176
Shares outstanding—2m——43m49m50m51m52m53m53m53m54m55m56m57m58m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AXSM vs SUPNCORT vs SUPNHRMY vs SUPN

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Supernus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Supernus Pharmaceuticals, Inc.